Implementation of guideline recommendations and outcomes in patients with idiopathic pulmonary fibrosis: Data from the IPF-PRO registry

被引:6
|
作者
Andrade, Joao A. de [1 ]
Kulkarni, Tejaswini [2 ]
Neely, Megan L. [3 ,4 ]
Hellkamp, Anne S. [3 ,4 ]
Case, Amy Hajari [5 ]
Guntupalli, Kalpalatha [6 ]
Bender, Shaun [7 ]
Conoscenti, Craig S. [7 ]
Snyder, Laurie D. [3 ,4 ]
机构
[1] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA
[2] Univ Alabama Birmingham, Birmingham, AL USA
[3] Duke Clin Res Inst, Durham, NC USA
[4] Duke Univ, Med Ctr, Durham, NC USA
[5] Piedmont Healthcare, Atlanta, GA USA
[6] Baylor Coll Med, Houston, TX 77030 USA
[7] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
关键词
Lung disease; Interstitial pulmonary fibrosis; Guideline; Hospitalization; Mortality; INTERSTITIAL LUNG-DISEASE; CLINICAL-PRACTICE; OXYGEN-THERAPY; ANTACID THERAPY; PERCEPTIONS; SPUTUM; INDEX; COUGH; EQ-5D;
D O I
10.1016/j.rmed.2021.106637
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Few data are available on the extent to which clinical practice is aligned with international guidelines for the management of idiopathic pulmonary fibrosis (IPF). We investigated the extent to which management guidelines for IPF have been implemented in the US IPF-PRO Registry and associations between implementation of guidelines and clinical outcomes. Methods: We assessed the implementation of eight recommendations in clinical practice guidelines within the 6 months after enrollment: visit to a specialized clinic; pulmonary function testing; use of oxygen in patients with resting hypoxemia and exercise-induced hypoxemia; referral for pulmonary rehabilitation; treatment of gastroesophageal reflux disease; initiation of anti-fibrotic therapy; referral for lung transplant evaluation. An implementation score was calculated as the number of recommendations achieved divided by the number for which the patient was eligible. Associations between implementation score and outcomes were analyzed using logistic regression and Cox proportional hazards models. Results: Among 727 patients, median (Q1, Q3) implementation score was 0.6 (0.5, 0.8). Patients with an implementation score >0.6 had greater disease severity than those with a lower score. Implementation was lowest for referral for pulmonary rehabilitation (19.5%) and lung transplant evaluation (22.3%). In unadjusted models, patients with higher implementation scores had a greater risk of death, death or lung transplant, and hospitalization, but no significant associations were observed in adjusted models. Conclusions: Management guidelines were more likely to be implemented in patients with IPF with greater disease severity. When adjusted for disease severity, no association was found between implementation of management guidelines and clinical outcomes.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort
    Jamie L. Todd
    Megan L. Neely
    Robert Overton
    Hillary Mulder
    Jesse Roman
    Joseph A. Lasky
    Joao A. de Andrade
    Mridu Gulati
    Howard Huang
    Thomas B. Leonard
    Christian Hesslinger
    Imre Noth
    John A. Belperio
    Kevin R. Flaherty
    Scott M. Palmer
    Lung, 2022, 200 : 11 - 18
  • [42] Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry
    Snyder, Laurie
    Neely, Megan L.
    Hellkamp, Anne S.
    O'Brien, Emily
    de Andrade, Joao
    Conoscenti, Craig S.
    Leonard, Thomas
    Bender, Shaun
    Gulati, Mridu
    Culver, Daniel A.
    Kaner, Robert J.
    Palmer, Scott
    Kim, Hyun Joo
    Asi, Wael
    Baker, Albert
    Beegle, Scott
    Belperio, John A.
    Condos, Rany
    Cordova, Francis
    Dilling, Daniel
    Flaherty, Kevin
    Glassberg, Marilyn
    Guntupalli, Kalpalatha
    Gupta, Nishant
    Case, Amy Hajari
    Hotchkin, David
    Huie, Tristan
    Kaner, Robert
    Kim, Hyun
    Kreider, Maryl
    Lancaster, Lisa
    Lasky, Joseph
    Lederer, David
    Lee, Doug
    Liesching, Timothy
    Lipchik, Randolph
    Lobo, Jason
    Mageto, Yolanda
    Menon, Prema
    Morrison, Lake
    Namen, Andrew
    Oldham, Justin
    Raj, Rishi
    Ramaswamy, Murali
    Russell, Tonya
    Sachs, Paul
    Safdar, Zeenat
    Sigal, Barry
    Silhan, Leann
    Strek, Mary
    RESPIRATORY RESEARCH, 2019, 20
  • [43] Associations of circulating matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases with clinically relevant outcomes in idiopathic pulmonary fibrosis: Data from the IPF-PRO Registry
    Amubieya, Olawale
    Todd, Jamie L.
    Neely, Megan L.
    Kaner, Robert J.
    Lasky, Joseph A.
    Namen, Andrew
    Hesslinger, Christian
    Palmer, Scott M.
    Weigt, S. Samuel
    Belperio, John A.
    PLOS ONE, 2024, 19 (10):
  • [44] Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry
    Laurie Snyder
    Megan L. Neely
    Anne S. Hellkamp
    Emily O’Brien
    Joao de Andrade
    Craig S. Conoscenti
    Thomas Leonard
    Shaun Bender
    Mridu Gulati
    Daniel A. Culver
    Robert J. Kaner
    Scott Palmer
    Hyun Joo Kim
    Respiratory Research, 20
  • [45] Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort
    Jamie L. Todd
    Richard Vinisko
    Yi Liu
    Megan L. Neely
    Robert Overton
    Kevin R. Flaherty
    Imre Noth
    L. Kristin Newby
    Joseph A. Lasky
    Mitchell A. Olman
    Christian Hesslinger
    Thomas B. Leonard
    Scott M. Palmer
    John A. Belperio
    BMC Pulmonary Medicine, 20
  • [46] Circulating Urokinase-Type Plasminogen Activator Receptor Protein Highly Correlates With the Severity of Idiopathic Pulmonary Fibrosis (IPF): Data From the IPF-PRO Registry
    Todd, J. L.
    Mulder, H.
    Neely, M. L.
    Belperio, J. A.
    Lasky, J. A.
    Luckhardt, T. R.
    Palmer, S. M.
    Hesslinger, C.
    Schlange, T.
    Leonard, T. B.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [47] Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis A Cross-Sectional Analysis of the IPF-PRO Registry
    O'Brien, Emily C.
    Hellkamp, Anne S.
    Neely, Megan L.
    Swaminathan, Aparna
    Bender, Shaun
    Snyder, Laurie D.
    Culver, Daniel A.
    Conoscenti, Craig S.
    Todd, Jamie L.
    Palmer, Scott M.
    Leonard, Thomas B.
    CHEST, 2020, 157 (05) : 1188 - 1198
  • [48] Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort
    Todd, Jamie L.
    Vinisko, Richard
    Liu, Yi
    Neely, Megan L.
    Overton, Robert
    Flaherty, Kevin R.
    Noth, Imre
    Newby, L. Kristin
    Lasky, Joseph A.
    Olman, Mitchell A.
    Hesslinger, Christian
    Leonard, Thomas B.
    Palmer, Scott M.
    Belperio, John A.
    BMC PULMONARY MEDICINE, 2020, 20 (01)
  • [49] Long-term Air Pollution Exposure Is Associated With Increased Severity of Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry
    Sack, C.
    Wojdyla, D.
    Macmurdo, M. G.
    Gassett, A.
    Kaufman, J. D.
    Raghu, G.
    Redlich, C. A.
    Li, P.
    Olson, A. L.
    Leonard, T. B.
    Todd, J. L.
    Neely, M. L.
    Snyder, L. D.
    Gulati, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [50] Gene-Based Collapsing Genetic Analyses to Identify Rare Protein-Coding Variants Associated with Susceptibility to Idiopathic Pulmonary Fibrosis (IPF): Data from the IPF-PRO Registry
    Povysil, G.
    Todd, J. L.
    Allen, A. S.
    Dilling, D. F.
    Kim, H. J.
    Neely, M. L.
    Noth, I.
    Ren, Z.
    Snyder, L. D.
    Strek, M. E.
    Swaminathan, A.
    Zhang, D.
    Hesslinger, C.
    Leonard, T. B.
    Goldstein, D. B.
    Palmer, S. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205